JELMYTO® Real-World Study Matches OLYMPUS in Cancer Response Rates
Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing reverse thermal gel indicated for primary chemoablative treatment of LG-UTUC in adults.
Brand Name : Jelmyto
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 04, 2024
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Salix Announces Phase 2 Study of RELISTOR® in Resectable HNSCC
Details : Relistor (methylnaltrexone bromide) is an opioid antagonist, its subcutaneous formulation is being investigated in patients with resectable head and neck squamous cell carcinoma.
Brand Name : Relistor
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 06, 2024
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Phase 4 Study Evaluates ADSTILADRIN® Use in Real-World Setting
Details : Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy delivering a human IFNα2b gene to the bladder for treating BCG-unresponsive non-muscle invasive bladder cancer.
Brand Name : Adstiladrin
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 24, 2024
Lead Product(s) : Dotatate Lutenium Lu-177
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lutathera (lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) is an Advanced Accelerator Applications RLT approved in the United States for the treatment of SSTR-positive GEP-NETs.
Brand Name : Lutathera
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 25, 2023
Lead Product(s) : Dotatate Lutenium Lu-177
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ciltacabtagene Autoleucel
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $650.0 million
Deal Type : Collaboration
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
Details : Legend Biotech entered into the agreement with Janssen to develop, manufacture and commercialize cilta-cel for the treatment of multiple myeloma. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy.
Brand Name : Cilta-cel
Molecule Type : Cell and Gene therapy
Upfront Cash : $350.0 million
February 11, 2022
Lead Product(s) : Ciltacabtagene Autoleucel
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $650.0 million
Deal Type : Collaboration
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NUBEQA significantly reduced the risk of death by 31%, offering men with non-metastatic castration-resistant prostate cancer (nmCRPC) extended survival for a greater chance of living longer.
Brand Name : Nubeqa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 08, 2021
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bristol Myers Squibb Statement on Opdivo (Nivolumab) Small Cell Lung Cancer U.S. Indication
Details : The trial demonstrated encouraging response rates and duration of response with Opdivo in SCLC, an aggressive and difficult-to-treat cancer.
Brand Name : Opdivo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 29, 2020
Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CIBMTR Completes Enrollment in Yescarta® Long-Term Post-Marketing Safety Study
Details : Yescarta is the first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Brand Name : Yescarta
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 08, 2020
Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable